Various new bulletins on RAC1 radio have included statements by Ernest Giralt, group leader of the Peptide and Protein Laboratory at IRB Barcelona, following the publication of an article on the compound created by his lab that is capable of transporting drugs in to the brain.
The Council recognizes the impact of his research in peptide chemistry with applications in innovative therapies for cancer
The "Ciutat de Barcelona" prize represents the highest recognition that gives the city to its citizens
SmartQuimic has interviewed Teresa Tarragó and Ernest Giralt, IRB Barcelona researchers and co-founders of the spin-off Iproteos, granted the EXPOQUIMIA ’14 award for the creation of IRP19, a new drug for treating cognitive deficits associated with schizophrenia.
Read the interview in SmartQuimic
“La Vanguardia”, together with other national and international media outlets, has published a news story about “Spark”, a project launched by a public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off located at PCB. IRB Barcelona, CRG, the University of the Bask Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project.
The aim of Spark is to carry out the first preclinical stage of the development of a first-in-class drug to prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia.
The Wall Street International Magazine has published in an article on the development of compounds with therapeutic purposes capable of crossing the blood-brain barrier, which protects the brain from infection. The article highlights recent projects led by Ernest Giralt, group leader of the Peptide and Protein Laboratory at IRB Barcelona and co-founder of the spin-off Iproteos, and includes many statements from the researcher.
Read the article in the Wall Street International Magazine (in Spanish)
The goal of «Spark» is to carry out the first preclinical stage of the development of a first-in-class drug that will prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia and other mental disorders, and to be able to start first-in-humans trials by 2016
The project, which has just won a 500,000 euro endorsement from the Ministry of Economy and Finance and FEDER funds through the “Retos-Colaboración” (Challenges-Collaboration) subprogram- will be developed by a consortium led by the biotech Iproteos -located at the Parc Cientific de Barcelona- and comprised by the company Ascil-Biopharm, IRB Barcelona, the Centre for Genomic Regulation and the University of the Basque Country
Currently there is no drug targetting the cognitive impairment associated with schizophrenia, the third most disabling disease even above paraplegia and blindness- according to the WHO and that affects about 24 million people worldwide. It is also the fifth disease with a higher annual cost to society, with more than 35,000 million euros cost only in the Europe Union
Researchers in Barcelona discover more potential candidates on the route to tailored, photo-switchable therapies by disproving design limitation
Radio 5 (RNE) interviews Meritxell Teixidó, associate researcher in the Peptide and Protein Laboratory at IRB Barcelona, about the line of investigation on substances capable of crossing the hematoencephalic barrier —a structure that protects the brain from infection. Teixidó talks about a new peptide that they have produced based on apamine, a peptide present in bee venom. This finding would allow the design of new drugs to treat diseases of the central nervous system. Another project related to these peptides is the treatment of glioblastoma, a joint project conducted with Joan Seoane, researcher at the “Hospital Vall d’Hebron” Oncology Institute (VHIO).
Listen to the interview...
The project, led by Natàlia Carulla, has been awarded funds from “La Marató de TV3” initiative held in 2013.
The project, which will be undertaken over three years, aims to verify a new therapeutic target to fight Alzheimer’s.
“La Sexta Columna” television programme has broadcasted a report about the initiative taken by families with relatives that suffer from Friedreich’s Ataxia, a rare illness with no cure. Joined in an association called Genefa, these families raised the funds necessary to launch a research project – involving IRB Barcelona - to find a treatment.
The programme featured Juan Carlos Baiges, head of the association, Meritxell Teixidó, partner researcher in the Peptide and Protein Laboratory at IRB Barcelona, and Javier López Nido, researcher at the Severo Ochoa Centre of Molecular Biology in Madrid, with whom Teixidó works in coordination to carry the project forward.